We used quartz optical fibers and laser excitation in developing single-fiber fluoroprobes, to be used to measure molecular fluorescence in minute volumes of body fluids. We illustrate and discuss the analytical capabilities of these fluoroprobes. Limits of detection for the anti-tumor drug doxorubicinare about 10 mol/L, by either conventional fluorescenceor sequentiallyexcited fluoroscencemodes of detection. We also report the results of preliminary in vivo measurements of doxorubicin in the interstitial fluids of humantumors, heterotransplantedin immune-deficient laboratory mice. The analytical capabilities of fluorescence spectrometry, which has been used in a variety of clinical analyses (1), have been extended by recent technological
In this work we measured concentrations of the antitumor drug doxorubicin by using the fluoroprobe and conventional fluorescence (CF) and sequentially excited fluorescence (SEF) techniques.'
The SEF process involves sequential resonant excitation, which can be depicted as 5o +hp1 -Si* + hv2 -* where S0, S,", and S, are the ground, first-excited, and Figure 1 shows a schematic diagram Concord, CA 94518; Model 126). The photomultiplier tube was cooled in solid CO2 during the SEF measurements.
Materials and Methods

Apparatus
We have evaluated two fluoroprobe designs for in vivo measurements in body fluids, differing primarily in the manner in which the body fluid is transported into the probe (seebelow). Two design characteristics were common to the fluoroprobes. First, their internal volumes were kept extremely small so we could perform our fluorescence measurements in the interstitial fluid of soft tissue. [It has been previously reported that interstitial fluids cannot be sampled in amounts sufficient for analysis (4) .] Second, we designed the fluoroprobes to contain a well-defined optically sampled chamber (microcuvette), so that the optically sampled volume in our measurements would be constant and unaffected by changes in the biological matrix.
Samples are transported into the fluoroprobes via either aspiration or capillary action. In our early in vivo experiments, using a previously described fluoroprobe (5), we used elaborate sample aspiration and expulsion procedures. However, with that aspiration-type fluoroprobe it was not possible to assure that after aspiration a uniform volume of interstitial fluid surrounded the fiber terminus, or that the fluid was completely expelled after the measurement. However, reliable sampling of interstitial fluid is possible with the fluoroprobe design shown in Figure 1 . We constructed this probe, which relies primarily on capillary action to sample fluids, by first stripping the protective coating and optical cladding to a distance of 2.0 cm from the terminus of a 200-pm diameter optical fiber. We then slid 2.0 cm of 600 pm (o.d.) x 240 m (i.d.) glass capillary tubing over the stripped optical fiber and attached this assembly, with epoxy glue, into a modified 20-gauge needle. A piece of heatshrinkable tubing was placed on the protected fiber such that the maximum distance the fiber could be withdrawn in the capillary tube was 5 mm. The available volume in the capillary tube was approximately 200 nL when the fiber was withdrawn this distance.
Reagents
Doxorubicin hydrochloride
was supplied by Adria Laboratories, Inc., Columbus, OH 43200. Blood determinations were performed with fresh whole blood, drawn in anticoagulant consisting of sodium citrate, sodium biphosphate, and 
Results and Discussion
In previous work, we demonstrated that the fluoroprobe apparatus is capable of obtaining both reproducible measurements and reproducible spectra (5). In addition, we discussed how using both conventional and nonlinear excited (e.g., SEF) modes of fluorescence detection can enhance spectral selectivity. In evaluating the ultimate utility of the fluoroprobe for in vivo analysis, however, the analytical parameter of sensitivity must be thoroughly considered. Fluoroprobe sensitivity is perhaps the most critical determinant for obtaining in vivo measurements of doxorubicin.
Accordingly,
the following discussion is primarily devoted to evaluating the sensitivity of the fluoroprobe technique.
Analytical calibration data for doxorubicin in water and whole blood were obtained with the aspiration-type fluoroprobe, the nitrogen-pumped dye laser being used for excitation. As Figure 2 illustrates, there is an inner filter roll-off effect at high doxorubicin concentrations. This behavior is characteristic of fluorescence spectrometry. Shorter effective pathlengths for measurements in the optically dense blood matrix (relative to H20) result in less exiting the optical fiber, thus decreasing the photon density, the effective pathlength for SEF is shorter than for CF. To estimate the effective pathlength for these measurements, we placed a bare, 200-pm-diameter fiber in a beaker containing a doxorubicin solution. A layer of black, optically absorbing material covered the bottom of the beaker. Using an optical fiber positioner to translate the fiber, we recorded signals for various distances between the fiber terminus and the blackened beaker bottom (Figure 3) . The effective pathlength for CF was slightly greater than 1.0mm, and for SEF slightly less than 0.5 nun.
Limits of detection can be determined from the calibration plots in Figure 2 For most of our in vivo measurements, we used the CF technique and the argon ion laser, at an output power of 50 mW, for excitation. Owing to limited access to that laser, we occasionally performed in vivo measurements by SEF, using the nitrogen-pumped dye laser for excitation. In consideration of the quadratic power dependence of the SEF-technique, we feel that SEF detection, using a pulsed laser capable of average and peak powers of approximately 100 mW and 1.0 MW, respectively (e.g., an excimer-pumped dye laser), would be the preferred method of making the in vivo measurements described in this report. Unfortunately, no such laser was available for this work.
The ability to use the fluoroprobe to measure doxorubicin in live tumor tissue was evaluated with the aforementioned laboratory mice. Throughout the in vivo work, the intravenous injection of toxic doxorubicin was a difficult experimental obstacle to overcome. The actual volume of delivery of the capillary-action-type fluoroprobe used to obtain the results shown in Figure 4c was determined by discharging a fairly concentrated doxorubicin solution from the fluoroprobe into 25 i.tL of methanol. We determined the concentration of the doxonibicin in this diluted solution by using the aforementioned HPLC with laser fluorometric detection. Comparison with an HPLC calibration plot for doxorubicin yielded a dilution factor of 150, from which we calculated that the effective volume of delivery of the fluoroprobe was 170 nL.
When the in vivo signal in Figure 4c had reached a steady value (approximately 5 mm after injection), we removed the fluoroprobe from the tumor, examined it for tissue fragments, and discharged its contents into 25 iL of methanol. By HPLC of this diluted sample, we calculated that its doxorubicin concentration was 2.8 pmol/L, or 420 jimollL in the undiluted interstitial fluid sample. This potential for providing independent analytical data necessary for calibrating the fluoroprobe signal, distinguishes the capillaryaction-type fluoroprobe from the other design tested.
In conclusion, we have explored the potential for performing in vivo molecular fluorescence measurements. Through the utilization of lasers and optical fibers, we have evaluated preliminary fluoroprobe designs, and hope that the basic theoretical and experimental framework provided by this work will stimulate exploration of clinical applications for fluoroprobes.
